Immunome (NASDAQ:IMNM) Hits New 1-Year Low – Here’s What Happened

Immunome, Inc. (NASDAQ:IMNM) shares reached a new 52-week low during mid-day trading on Monday . The company traded as low as $8.51 and last traded at $8.88, with a volume of 395083 shares. The stock had previously closed at $9.34.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Piper Sandler reduced their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Wedbush restated an “outperform” rating and set a $33.00 target price on shares of Immunome in a report on Monday. Finally, Lifesci Capital started coverage on Immunome in a report on Tuesday. They issued an “outperform” rating and a $20.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome presently has an average rating of “Buy” and a consensus target price of $27.17.

Immunome Trading Up 5.5 %

The business has a 50 day simple moving average of $10.09 and a two-hundred day simple moving average of $11.89. The stock has a market cap of $734.75 million, a price-to-earnings ratio of -1.14 and a beta of 1.93.

Insider Activity

In related news, CEO Clay B. Siegall purchased 150,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its holdings in shares of Immunome by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock valued at $359,000 after acquiring an additional 1,520 shares during the last quarter. Sequoia Financial Advisors LLC boosted its holdings in Immunome by 11.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock worth $202,000 after purchasing an additional 2,000 shares during the period. Intech Investment Management LLC increased its stake in Immunome by 26.5% during the fourth quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock valued at $201,000 after purchasing an additional 3,974 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Immunome by 3.5% during the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after purchasing an additional 4,874 shares during the period. Finally, Cerity Partners LLC raised its holdings in shares of Immunome by 10.5% during the third quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after purchasing an additional 5,043 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.